492 results on '"Sulkowski M."'
Search Results
102. 10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB
103. 1421 HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS
104. 50 BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN FOR THE TREATMENT OF HCV/HIV CO-INFECTED PATIENTS: END OF TREATMENT (WEEK 48) INTERIM RESULTS
105. 1185 CHARACTERIZATION OF HCV NS3 VARIANTS THAT EMERGED DURING VIROLOGIC BREAKTHROUGH AND RELAPSE FROM BI 201335 PHASE II SILEN-C2 STUDY IN PEGIFN/RBV TREATMENT-EXPERIENCED PATIENTS
106. 1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3
107. 1209 IMPACT OF EARLY RESPONSE DEFINITIONS ON DURATION AND OUTCOME OF TREATMENT WITH BI201335 PLUS PR
108. Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
109. Hip bone geometry in HIV/HCV-co-infected men and healthy controls
110. Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C
111. 1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12
112. 127 PHOSPHODIESTERASE POLYMORPHISMS MAY BE ASSOCIATED WITH BASELINE THYROID STIMULATING HORMONE (TSH) AND PEGINTERFERON TREATMENT INDUCED HYPOTHYROIDISM IN PATIENTS WITH CHRONIC HEPATITIS C
113. 1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY
114. 1191 BASELINE LIVER STIFFNESS MEASURED BY TRANSIENT ELASTOGRAPHY IS INDEPENDENTLY ASSOCIATED WITH RISK OF END-STAGE LIVER DISEASE AND DEATH AMONG HIV/HCV CO-INFECTED ADULTS
115. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial
116. 310 MARKED SPIROMETRY DECLINE IN PATIENTS WITH CHRONIC HEPATITIS C DURING TREATMENT WITH ALBINTERFERON ALFA-2B IS SIMILAR TO PEGINTERFERON ALFA-2A
117. 778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS
118. 1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV
119. 303 SHIFTS IN CHILD–PUGH SCORE IN PATIENTS COINFECTED WITH HIV-HCV UNDERGOING TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN ARE NOT PREDICTIVE OF HEPATIC DECOMPENSATION
120. 287 EVALUATING VIROLOGIC RESPONSE WITHIN 2–4 WEEKS HAS HIGH POSITIVE/NEGATIVE PREDICTIVE VALUES FOR SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C DURING TREATMENT
121. 269 DYNAMICS OF APOPTOTIC ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH ALBINTERFERON ALFA-2B OR PEGINTERFERON ALFA-2A
122. 416 LONGITUDINAL PROSPECTIVE COMPARISON OF FIBROSURE AND TRANSIENT ELASTOGRAPHY IN RELATION TO VIROLOGIC RESPONSE: A SUBSTUDY OF THE PHASE 3 ALBINTERFERON ALFA-2B TRIALS
123. 2015 GENOME WIDE ANALYSIS OF PATIENTS FROM THE IDEAL STUDY IDENTIFIES A CAUSAL ROLE FOR ITPA GENETIC VARIATION IN RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA
124. Determination of Trace Elements in Small Amounts of Specimen on Filter Material by Wavelength-Dispersive X-Ray Fluorescence Spectrometry
125. 95 EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS
126. 1041 EFFICACY AND SAFETY OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT- NAIVE, CHRONIC HEPATITIS C GENOTYPE 1 (CHC G1) PATIENTS
127. 126 HEMOGLOBIN DECLINE IS ASSOCIATED WITH SVR AMONG HCV GENOTYPE 1-INFECTED PERSONS TREATED WITH PEGINTERFERON (PEG)/RIBAVIRIN (RBV): ANALYSIS FROM THE IDEAL STUDY
128. 104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS
129. 991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY
130. 834 ANTIVIRAL ACTIVITY AND CHANGES IN B-LYMPHOCYTE STIMULATOR PROTEIN LEVELS DURING TREATMENT WITH ALBINTERFERON ALFA-2B/RIBAVIRIN IN PRIOR INTERFERON-THERAPY NONRESPONDERS
131. [6] VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, COMPARED TO PEG INTERFERON/RIBAVIRIN (PEGIFN/RBV) RETREATMENT IN PATIENTS WITH HCV-1 INFECTION AND PRIOR NON-RESPONSE TO PEGIFN/RBV: ONE-YEAR RESULTS
132. Global transcriptional effects of PEG-IFN-α and ribavirin on peripheral blood cells obtained from patients with chronic hepatitis C
133. CA 67-Réponse virologique prolongée à l’albumine interféron alfa-2b en combinaison avec la ribavirine chez des malades non répondeurs à un traitement préalable par interféron et ribavirine : résultats intermédiaires d’une étude de phase 2
134. 39 Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegifn/RBV) re-treatment in hepatitis patients with prior non-response to PEGIFN/RBV: Week 24 results
135. Structural and optical properties of BaTiO3thin films prepared by radio-frequency magnetron sputtering at various substrate temperatures
136. Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study
137. Treatment of Chronic Hepatitis B in HIV-Infected Persons: Thinking Outside the Black Box
138. Liver enzyme values in injection drug users with chronic hepatitis C
139. 456 Safety, pharmacokinetics and pharmacodynamic results of higher doses of albuferon in a phase single and double dose-escalation study in treatment experienced subjects with chronic hepatitis C
140. 507 Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with HCV/HIV co-infection: Results from the aids pegasys ribavirin international co-infectio (abstract withdrawn)
141. 1125 Hepatotoxicity associated with the antiretroviral therapy (ART) containing protease inhibitors (PIS) with or without pharmacokinetic boosting by low-dose ritonavir (RTV)
142. PGI15 - Health and economic outcomes of sofosbuvir therapy as predicted by a Markov model in the HCV/HIV co-infected cohort
143. QOL benefits observed as early as week 2 with peginterferon alfa-2a (40KD) (PEGASYS) in combination with ribavirin (RBV) versus interferon alfa-2b plus RBV
144. Structural and electrical properties of In2O3:Sn films prepared by radio-frequency sputtering
145. Once-weekly recombinant human erythropoetin (Epoetin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus (HCV)-infected patients receiving interferon-α-2b (IFN)/RBV combination therapy
146. Infectious Arthritis Due to Propionibacterium acnes in a Prosthetic Joint
147. Peginterferon-α-2a (40kD) and Ribavirin in Patients with Chronic Hepatitis C: A Phase II Open-Label Study.
148. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.
149. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States.
150. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.